Pender Fund Capital Management Ltd. Zymeworks Inc. Transaction History

Pender Fund Capital Management Ltd.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Jul 17, 2018	SELL	$11.13 - $21.86 $3.62 Million - $7.11 Million	-325,058 Closed	0 $0
Q1 2018 May 04, 2018	BUY	$7.93 - $13.41 $2.58 Million - $4.36 Million	325,058 New	325,058 $0

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Pender Fund Capital Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Pender Fund Capital Management Ltd. with notifications on news.